Fortress Biotech is a biopharmaceutical company focused on acquiring, developing and commercializing pharmaceutical and biotechnology products and product candidates. Through its partner company, Co. markets the following dermatology products: Ximino®, which is a tetracycline-class drug indicated to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox®, which is a tetracycline-class drug indicated as adjunctive therapy for severe acne; and Ceracade®, which is a steroid-free, ceramide-dominant formulation used to treat dry skin conditions and to manage and relieve the burning and itching associated with various types of dermatitis and radiation dermatitis. The FBIO stock yearly return is shown above.
The yearly return on the FBIO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the FBIO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|